India's Shasun Move Into Japan Signals Changing Attitudes Toward API Makers
This article was originally published in PharmAsia News
Executive SummaryJapanese drug makers are the target of a major effort by India's Shasun Chemicals and Drugs to have a large presence as a supplier of active pharmaceutical ingredients. Shasun is a leading producer of APIs and intermediaries and the world's leading maker of ibuprofen. The firm is a major supplier to leading Western drug makers, but has not had much of a presence in Japan because its pharmas tended not to outsource such work. The economic climate is leading many Japanese firms to rethink that policy as a way to cut costs. (Click here for more - a subscription may be required
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.